Compare ADMA Biologics Inc (ADMA) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Enbridge Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Enbridge Inc trades at $51.68 (market cap $112.26B). The key difference: Enbridge Inc is far larger — about 51.5× ADMA Biologics Inc's market cap, and Enbridge Inc pays a 5.36% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ENB | |
|---|---|---|
Market Cap | $2.18B | $112.26B |
Sector | Health | Energy |
52-Week High | $20.38 | $58.04 |
52-Week Low | $7.60 | $45.23 |
Enterprise Value | $2.25B | $196.07B |
Dividend Yield | — | 5.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
ENB trades at $51.28, down 0.81% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.46, beating estimates, and maintains a strong dividend track record with recent payouts of $0.97. Revenue grew to $65.19B in 2025, with a net income margin of 7.34%, though debt levels have increased.
Outlook is mixed; analyst consensus is evenly split between Buy and Hold, with a 48% Buy rating. Key opportunities include a $41B project backlog and consistent dividend growth, while risks involve high debt, regulatory challenges, and volatile cash flows. The stock's valuation appears reasonable with a P/E of 27.74.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
